Management of Inferior Q Waves on EKG

Initial Diagnostic Approach

The American Heart Association recommends that inferior Q waves on EKG require immediate assessment to distinguish acute myocardial infarction from prior infarction, with management determined by the presence or absence of ST-segment elevation and cardiac biomarker elevation 1, 2
Established Q waves ≥0.04 seconds in the inferior leads (II, III, aVF) suggest prior myocardial infarction and indicate a high likelihood of significant coronary artery disease, but are less helpful in diagnosing acute unstable angina [2, 3, 4 is ignored in favor of 2 and 3]
Isolated Q waves in lead III alone may be a normal finding, especially when there are no repolarization abnormalities in the other inferior leads (II, aVF) 2, 3, 5

The European Society of Cardiology suggests that the presence of ST-segment elevation or depression accompanying Q waves suggests acute or evolving infarction and requires immediate reperfusion therapy consideration [4 is ignored in favor of other references, 6]
Obtain serial cardiac biomarkers (troponin) immediately—do not wait for results to initiate reperfusion therapy if ST-elevation is present 6
Compare with prior ECGs when available, as this dramatically improves diagnostic accuracy 1, 5

Patients with Q waves plus ST-segment deviation are at higher risk for death than those with Q waves and normal ST segments or T-wave changes only 1
Transient ST-segment changes ≥0.05 mV (0.5 mm) during symptomatic episodes that resolve when asymptomatic strongly suggest acute ischemia and very high likelihood of severe coronary artery disease 1, 3, 5
Up to 25% of NSTEMI patients with elevated CK-MB develop Q waves during their hospital stay 3, 5

For inferior Q waves WITH ST-Elevation, activate reperfusion therapy immediately (fibrinolysis or primary PCI) as these patients qualify for acute STEMI management 3, 5
For inferior Q waves WITHOUT ST-Elevation, measure serial cardiac biomarkers to distinguish NSTEMI from prior infarction 1
If biomarkers are elevated, manage as NSTEMI with antiplatelet therapy, anticoagulation, and consideration for early invasive strategy based on risk score 1

Perform 2D echocardiography to assess regional wall motion abnormalities, which occur within seconds of coronary occlusion and help distinguish acute from chronic changes 6
Absence of wall motion abnormalities excludes major myocardial infarction 6
Echocardiography also excludes non-ischemic causes of Q waves including hypertrophic cardiomyopathy, infiltrative diseases, and other cardiomyopathies 3, 6

The European Society of Cardiology recommends examining leads II and aVF for Q waves ≥0.04 seconds or ST-segment elevation ≥0.1 mV to confirm inferior wall involvement in patients with Q waves in lead III 7, 8
The presence of ST-segment elevation in two or more contiguous inferior leads (II, III, aVF) is indicative of STEMI requiring immediate reperfusion therapy, according to the European Heart Journal 9, 10
Recording right precordial leads (V3R and V4R) is essential to identify concomitant right ventricular infarction, which occurs frequently with inferior STEMI, as recommended by the European Heart Journal 10

The European Heart Journal suggests that Q waves in leads II, III, and aVF with ST-segment elevation ≥0.1 mV is a high-risk pattern requiring immediate reperfusion 10, 7
The European Society of Cardiology recommends initiating dual antiplatelet therapy (aspirin plus P2Y12 inhibitor) immediately in patients with NSTEMI, defined as Q waves in inferior leads without ST-elevation but with elevated troponin 11

The European Heart Journal recommends activating primary PCI within 120 minutes or administering fibrinolytic therapy if PCI is unavailable in patients with STEMI 10
The European Society of Cardiology suggests administering antithrombotic therapy, including aspirin, P2Y12 inhibitor, and anticoagulation with unfractionated heparin or enoxaparin, in patients with STEMI 10, 11

The European Heart Journal recommends placing patients with NSTEMI on continuous ECG monitoring with defibrillation capability and initiating dual antiplatelet therapy immediately 11
The European Society of Cardiology suggests performing early invasive strategy (coronary angiography) within 12-24 hours for high-risk patients with NSTEMI 11